Cargando…

Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge

Non-alcoholic steatohepatitis (NASH) is the most common chronic liver disease worldwide, and the fastest growing indication for liver transplantation in the United States. NASH is now the leading etiology for liver transplantation in women, the second leading indication for men, and the most common...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steggerda, Justin A, Mahendraraj, Krishnaraj, Todo, Tsuyoshi, Noureddin, Mazen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403794/ https://www.ncbi.nlm.nih.gov/pubmed/32821068 http://dx.doi.org/10.3748/wjg.v26.i28.4018

Ejemplares similares

Higher thresholds for the utilization of steatotic allografts in liver transplantation: Analysis from a U.S. national database
por: Steggerda, Justin A., et al.
Publicado: (2020)

Incidental finding of non-alcoholic steatohepatitis-cirrhosis
por: Adrian, Therese, et al.
Publicado: (2022)

Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis
por: Stine, Jonathan G, et al.
Publicado: (2017)

Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
por: Barritt, A. Sidney, et al.
Publicado: (2022)

Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
por: Noureddin, Mazen, et al.
Publicado: (2023)

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals
por: Noureddin, Mazen, et al.
Publicado: (2018)

Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004–2018 Analysis
por: Noureddin, Nabil, et al.
Publicado: (2020)

Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis
por: Stine, Jonathan G., et al.
Publicado: (2018)

Outcomes and potential surrogate markers for future clinical trials of non‐alcoholic steatohepatitis cirrhosis
por: Rivera‐Esteban, Jesús, et al.
Publicado: (2021)

13 CHEMOPREVENTIVE EFFECT OF STATIN ON HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC STEATOHEPATITIS PATIENTS WITH CIRRHOSIS
por: Al-Yaman, Wael A., et al.
Publicado: (2021)

Hepatocellular Carcinoma in the Pediatric Population: A Population Based Clinical Outcomes Study Involving 257 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973–2011)
por: Lau, Christine S. M., et al.
Publicado: (2015)

Atypical teratoid rhabdoid tumors: a population-based clinical outcomes study involving 174 patients from the Surveillance, Epidemiology, and End Results database (1973–2010)
por: Lau, Christine SM, et al.
Publicado: (2015)

Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database
por: Lau, Christine SM, et al.
Publicado: (2017)

Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting
por: Balitzer, Dana, et al.
Publicado: (2022)

A Clinical Tool to Guide Selection and Utilization of Marginal Donor Livers With Graft Steatosis in Liver Transplantation
por: Steggerda, Justin A., et al.
Publicado: (2022)

Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis
por: Seen, Tasur Kumar, et al.
Publicado: (2021)

COVID-19 Alcoholic Cirrhosis and Non-Alcoholic Steatohepatitis Cirrhosis Outcomes among Hospitalized Patients in the United States: Insight from National Inpatient Sample Database
por: Kapuria, Devika, et al.
Publicado: (2022)

Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases
por: Safaei, Akram, et al.
Publicado: (2016)

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
por: Golabi, Pegah, et al.
Publicado: (2018)

Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic
por: Mouzaki, Marialena, et al.
Publicado: (2012)

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
por: Dufour, Jean-François, et al.
Publicado: (2020)

Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: A ten-year retrospective study
por: Xiong, Ji, et al.
Publicado: (2015)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Alnimer, Lynna, et al.
Publicado: (2023)

Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973–2012)
por: Mahendraraj, Krishnaraj, et al.
Publicado: (2017)

Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973–2012)
por: Mahendraraj, Krishnaraj, et al.
Publicado: (2016)

Gallbladder Carcinoma in the United States: A Population Based Clinical Outcomes Study Involving 22,343 Patients from the Surveillance, Epidemiology, and End Result Database (1973–2013)
por: Lau, Christine S. M., et al.
Publicado: (2017)

Pulmonary Hypertension as a Rare Complication After Orthotopic Liver Transplant in a Patient With Non-alcoholic Steatohepatitis (NASH) Cirrhosis Complicated by Hepatopulmonary Syndrome
por: Dadlani, Apaar, et al.
Publicado: (2022)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia
por: Xiao, Jieling, et al.
Publicado: (2022)

Diet Quality Association with Nonalcoholic Fatty Liver Disease by Cirrhosis Status: The Multiethnic Cohort
por: Park, Song-Yi, et al.
Publicado: (2020)

Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis
por: Stepanova, Maria, et al.
Publicado: (2015)

Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease
por: Teng, Pai-Chi, et al.
Publicado: (2023)

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2022)

Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study
por: Haldar, Debashis, et al.
Publicado: (2019)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis
por: Josefsson, Axel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_anlpiqqeo5hken1e73kfa0r260